These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 30568391)
41. Pelvic exenterations combined with cytoreductions for T4 rectal cancers with peritoneal metastasis: a safety analysis. Kazi M; Raghavan S; Desouza A; Saklani A ANZ J Surg; 2024 Apr; 94(4):702-707. PubMed ID: 38012077 [TBL] [Abstract][Full Text] [Related]
42. Indications for primary and secondary exenterations in patients with cervical cancer. Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276 [TBL] [Abstract][Full Text] [Related]
43. Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. Yamada K; Ishizawa T; Niwa K; Chuman Y; Aikou T Dis Colon Rectum; 2002 Aug; 45(8):1078-84. PubMed ID: 12195193 [TBL] [Abstract][Full Text] [Related]
44. Feasibility of a tailored operative strategy from organ preservation to pelvic exenteration for cT4 rectal cancer depending on neoadjuvant response. Fleming C; Harji D; Fernandez B; François MO; Assenat V; Gilles P; Clément M; Robert G; Denost Q Int J Colorectal Dis; 2024 Jul; 39(1):123. PubMed ID: 39085478 [TBL] [Abstract][Full Text] [Related]
45. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer]. Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217 [No Abstract] [Full Text] [Related]
46. Propensity Score-Matched Analysis of Laparoscopic versus Open Surgery for Non-Metastatic Rectal Cancer. Sakolprakaikij K; Yolsuriyanwong K; Wangkulangkul P; Bwaloy P; Cheewatanakornkul S Asian Pac J Cancer Prev; 2021 Dec; 22(12):3967-3975. PubMed ID: 34967578 [TBL] [Abstract][Full Text] [Related]
47. Abdominoperineal resection for rectal cancer at a specialty center. Nissan A; Guillem JG; Paty PB; Douglas Wong W; Minsky B; Saltz L; Cohen AM Dis Colon Rectum; 2001 Jan; 44(1):27-35; discussion 35-6. PubMed ID: 11805560 [TBL] [Abstract][Full Text] [Related]
48. Surgical, survival and quality of life outcomes in over 1000 pelvic exenterations: lessons learned from a large Australian case series. Steffens D; Solomon MJ; Lee P; Austin K; Koh C; Byrne C; Karunaratne S; Hatcher S; Taylor K; McBride K ANZ J Surg; 2023 May; 93(5):1232-1241. PubMed ID: 36869215 [TBL] [Abstract][Full Text] [Related]
49. Pelvic exenteration and composite sacral resection in the surgical treatment of locally recurrent rectal cancer. Gawad W; Khafagy M; Gamil M; Fakhr I; Negm M; Mokhtar N; Lotayef M; Mansour O J Egypt Natl Canc Inst; 2014 Sep; 26(3):167-73. PubMed ID: 25150132 [TBL] [Abstract][Full Text] [Related]
50. Persistent High Rate of Positive Margins and Postoperative Complications After Surgery for cT4 Rectal Cancer at a National Level. de Nes LCF; Drager LD; Verstegen MG; Burger JWA; Tanis PJ; de Wilt JHW; Dis Colon Rectum; 2021 Apr; 64(4):389-398. PubMed ID: 33651005 [TBL] [Abstract][Full Text] [Related]
51. [Total pelvic exenteration and rectal cancer. Apropos of 20 cases]. Lasser P; Doidy L; Elias D; Lusinchi A; Sabourin JC; Bonvalot S; Ducreux M Chirurgie; 1999 Jun; 124(3):252-7. PubMed ID: 10429298 [TBL] [Abstract][Full Text] [Related]
52. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Milne T; Solomon MJ; Lee P; Young JM; Stalley P; Harrison JD; Austin KK Dis Colon Rectum; 2014 Oct; 57(10):1153-61. PubMed ID: 25203370 [TBL] [Abstract][Full Text] [Related]
53. Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer. Wiig JN; Poulsen JP; Larsen S; Braendengen M; Waehre H; Giercksky KE Eur J Surg; 2002; 168(1):42-8. PubMed ID: 12022371 [TBL] [Abstract][Full Text] [Related]
54. Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry. Roodbeen SX; Penna M; van Dieren S; Moran B; Tekkis P; Tanis PJ; Hompes R; J Natl Compr Canc Netw; 2021 Aug; 19(11):1232-1240. PubMed ID: 34404028 [TBL] [Abstract][Full Text] [Related]
55. The role of pelvic exenteration in the management of recurrent rectal cancer. Kakuda JT; Lamont JP; Chu DZ; Paz IB Am J Surg; 2003 Dec; 186(6):660-4. PubMed ID: 14672775 [TBL] [Abstract][Full Text] [Related]
56. [Clinical study of using basement membrane biological products in pelvic floor reconstruction during pelvic exenteration]. Chen GL; Wang YL; Zhang X; Tao Y; Sun YH; Chen JN; Wang SQ; Su N; Wang ZG; Zhang J Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Mar; 26(3):268-276. PubMed ID: 36925127 [No Abstract] [Full Text] [Related]
57. Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer. Platt E; Dovell G; Smolarek S Tech Coloproctol; 2018 Nov; 22(11):835-845. PubMed ID: 30506497 [TBL] [Abstract][Full Text] [Related]
58. Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer. Caycedo-Marulanda A; Lee L; Chadi SA; Verschoor CP; Crosina J; Ashamalla S; Brown CJ; JAMA Netw Open; 2021 Feb; 4(2):e2036330. PubMed ID: 33533932 [TBL] [Abstract][Full Text] [Related]
59. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: Overall survival and quality of life. Quyn AJ; Austin KK; Young JM; Badgery-Parker T; Masya LM; Roberts R; Solomon MJ Eur J Surg Oncol; 2016 Jun; 42(6):823-8. PubMed ID: 26947962 [TBL] [Abstract][Full Text] [Related]
60. Factors associated with oncologic outcomes after abdominoperineal resection compared with restorative resection for low rectal cancer: patient- and tumor-related or technical factors only? Reshef A; Lavery I; Kiran RP Dis Colon Rectum; 2012 Jan; 55(1):51-8. PubMed ID: 22156867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]